Yesterday, March 15, 2016, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $710.84 to $145,264,601.52.

Highlighted Stocks Traded by Insiders:

PetMed Express (PETS) - FREE Research Report

Rosenbloom Bruce S, who is Chief Financial Officer at PetMed Express, sold 3,000 shares at $17.25 on March 15, 2016. Following this transaction, the Chief Financial Officer owned 47,767 shares meaning that the stake was reduced by 5.91% with the 3,000-share transaction.

The shares most recently traded at $17.33, up $0.08, or 0.46% since the insider transaction. Historical insider transactions for PetMed Express go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,750
  • 24-Week # shares sold: 6,750

The average volume for PetMed Express has been 255,300 shares per day over the past 30 days. PetMed Express has a market cap of $353.5 million and is part of the health care sector and drugs industry. Shares are up 2.04% year-to-date as of the close of trading on Tuesday.

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. The stock currently has a dividend yield of 4.14%. The company has a P/E ratio of 17.4. Currently, there are no analysts who rate PetMed Express a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PETS - FREE

TheStreet Quant Ratings rates PetMed Express as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and good cash flow from operations. We feel its strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full PetMed Express Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Buffalo Wild Wings (BWLD) - FREE Research Report

Smith Sally J, who is CEO & President at Buffalo Wild Wings, sold 2,000 shares at $160.06 on March 15, 2016. Following this transaction, the CEO & President owned 60,231 shares meaning that the stake was reduced by 3.21% with the 2,000-share transaction.

The shares most recently traded at $154.62, down $5.44, or 3.52% since the insider transaction. Historical insider transactions for Buffalo Wild Wings go as follows:

  • 4-Week # shares bought: 315
  • 4-Week # shares sold: 637
  • 12-Week # shares bought: 315
  • 12-Week # shares sold: 4,637
  • 24-Week # shares bought: 315
  • 24-Week # shares sold: 14,637

The average volume for Buffalo Wild Wings has been 609,500 shares per day over the past 30 days. Buffalo Wild Wings has a market cap of $3.0 billion and is part of the services sector and leisure industry. Shares are down 2.74% year-to-date as of the close of trading on Tuesday.

Buffalo Wild Wings, Inc. engages in the ownership, operation, and franchise of restaurants worldwide. The company's restaurants provide various food products and alcoholic beverages. The company has a P/E ratio of 32.4. Currently, there are 11 analysts who rate Buffalo Wild Wings a buy, 1 analyst rates it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BWLD - FREE

TheStreet Quant Ratings rates Buffalo Wild Wings as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, increase in net income and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Buffalo Wild Wings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Avinger (AVGR) - FREE Research Report

Ferguson Matthew, who is Chief Financial Officer at Avinger, bought 1,500 shares at $11.37 on March 15, 2016. Following this transaction, the Chief Financial Officer owned 18,754 shares meaning that the stake was boosted by 8.69% with the 1,500-share transaction.

The shares most recently traded at $13.05, up $1.68, or 12.9% since the insider transaction.

The average volume for Avinger has been 635,900 shares per day over the past 30 days. Avinger has a market cap of $133.5 million and is part of the health care sector and health services industry. Shares are unchanged year-to-date as of the close of trading on Monday.

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe.

Exclusive Offer: Get the latest Stock Analysis on AVGR - FREE

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.